Gufic Biosciences (509079) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
14 Aug, 2026Executive summary
Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and the incorporation of a new subsidiary in the Philippines.
The new subsidiary will focus on marketing, sales, and distribution of pharmaceutical products in the Philippines, with an investment of up to USD 250,000 and 99.99% ownership.
Financial highlights
Consolidated revenue from operations for Q1 FY27 was ₹26,081.80 lakhs, up from ₹22,691.15 lakhs in Q1 FY26.
Consolidated net profit for Q1 FY27 was ₹2,231.28 lakhs, compared to ₹1,307.04 lakhs in Q1 FY26.
Basic and diluted EPS for Q1 FY27 stood at ₹2.22, up from ₹1.30 in Q1 FY26.
Total comprehensive income for Q1 FY27 was ₹2,239.54 lakhs.
Outlook and guidance
Expansion into the Philippines is expected to facilitate business growth and international presence.
Latest events from Gufic Biosciences
- Record Q4 revenue and profit, segment growth, and dividend set stage for margin improvement.509079
Q4 25/26 - Q3 FY26 revenue rose YoY; Indore ramp-up and regulatory wins to drive 15-20% FY27 growth.509079Q3 25/26
- Q2 FY26 revenue rose 12.8% YoY, led by Indore ramp-up and international expansion.509079Q2 25/26
- Q1 FY26 revenue up 12% YoY, Indore ramp-up, margin gains, and auditors re-appointed.509079Q1 25/26
- Stable H1 FY25 results, Indore facility operational, and global expansion accelerating.509079Q2 24/25
- Q1 FY25 profit rose with stable margins and global expansion as Indore facility ramps up.509079Q1 24/25
- Q4 revenue and EBITDA rose YoY, but margins and profit fell; dividend and global expansion moves approved.509079Q4 24/25
- Indore facility launch and global approvals drive growth, but margins and EPS declined YoY.509079Q3 24/25